/

Elicera in brief Board Team Advisors Elicera's history

Immuno-oncology

What is immuno-oncology?
CAR T-cell therapy Oncolytic virus

CAR T-cell therapy Challenges Mode-of-action Scientific publications

Pipeline ELC-301 ELC-401 ELC-201 ELC-100 Clinical trials Patent portfolio

Press Releases Corporate Governance the Share Financial Reports Financial Calendar Events Share issues Analyst Coverage

News Press Releases

/

Financial Calendar

Q2-report: 2023-08-29
Q3-report: 2023-11-28
Year-End Report: 2024-02-13
AGM: 2024-05-16
Q1-report: 2024-05-27
Q2-report: 2024-08-29
Q3-report: 2024-11-28
Year-End Report: 2025-02-03

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Contact us

Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬

Org.nr: 556966-4955

Integrity Policy

Follow us

By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.